RAFAEL HOLDINGS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
RAFAEL HOLDINGS, INC. (RFL) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $136.97 million for the 9-month period ending 2023-04-30, per its 10-Q filed 2023-06-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2023-06-13
- RAFAEL HOLDINGS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-04-30 was $65.59M.
- RAFAEL HOLDINGS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-01-31 was $48.46M.
- RAFAEL HOLDINGS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-10-31 was $22.92M.
- RAFAEL HOLDINGS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-07-31 was $26.00M.
- RAFAEL HOLDINGS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $28.50M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2023-04-30 | $65.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | $114.05M derived: sum of 2 quarters · filed 2023-06-13 | $136.97M 10-Q · filed 2023-06-13 | $162.97M derived: sum of 4 quarters · filed 2023-06-13 |
| 2023-01-31 | $48.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-14 | $71.38M 10-Q · filed 2023-03-14 | $97.38M derived: sum of 3 quarters · filed 2023-03-14 | |
| 2022-10-31 | $22.92M 10-Q · filed 2022-12-13 | $48.92M derived: sum of 2 quarters · filed 2022-12-13 | ||
| 2022-07-31 | $26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | $28.50M 10-K · filed 2022-10-31 | ||
| 2022-04-30 | $2.50M 10-Q · filed 2023-06-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |